Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Diminished global arginine bioavailability as a metabolic defect in chronic systolic heart failure.

Tang WH, Shrestha K, Wang Z, Troughton RW, Klein AL, Hazen SL.

J Card Fail. 2013 Feb;19(2):87-93. doi: 10.1016/j.cardfail.2013.01.001.

2.

Nitric oxide bioavailability and adiponectin production in chronic systolic heart failure: relation to severity of cardiac dysfunction.

Tang WH, Shrestha K, Tong W, Wang Z, Troughton RW, Borowski AG, Klein AL, Hazen SL.

Transl Res. 2013 Jul;162(1):26-33. doi: 10.1016/j.trsl.2013.02.005. Epub 2013 Mar 13.

3.

Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk.

Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL.

J Am Coll Cardiol. 2009 Jun 2;53(22):2061-7. doi: 10.1016/j.jacc.2009.02.036.

4.

Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure.

Tang WH, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, Klein AL, Hazen SL.

J Card Fail. 2015 Feb;21(2):91-6. doi: 10.1016/j.cardfail.2014.11.006. Epub 2014 Nov 20.

5.

Protein carbamylation in chronic systolic heart failure: relationship with renal impairment and adverse long-term outcomes.

Tang WH, Shrestha K, Wang Z, Borowski AG, Troughton RW, Klein AL, Hazen SL.

J Card Fail. 2013 Apr;19(4):219-24. doi: 10.1016/j.cardfail.2013.02.001. Epub 2013 Mar 19.

6.

Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure.

Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B, Hu B, Troughton RW, Klein AL, Hazen SL.

Eur Heart J. 2008 Oct;29(20):2506-13. doi: 10.1093/eurheartj/ehn360. Epub 2008 Aug 6.

7.

Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure.

Tang WH, Wu Y, Mann S, Pepoy M, Shrestha K, Borowski AG, Hazen SL.

Circ Heart Fail. 2011 Jan;4(1):59-64. doi: 10.1161/CIRCHEARTFAILURE.110.958348. Epub 2010 Nov 9.

8.

Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1.

Shao Z, Wang Z, Shrestha K, Thakur A, Borowski AG, Sweet W, Thomas JD, Moravec CS, Hazen SL, Tang WH.

J Am Coll Cardiol. 2012 Mar 27;59(13):1150-8. doi: 10.1016/j.jacc.2011.12.022.

9.

Impact of myocardial function on cystatin C measurements in chronic systolic heart failure.

Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, Martin MG, Borowski AG, Jasper S, Starling RC, Klein AL.

J Card Fail. 2008 Jun;14(5):394-9. doi: 10.1016/j.cardfail.2008.01.006. Epub 2008 May 27.

PMID:
18514931
10.

Global arginine bioavailability, a marker of nitric oxide synthetic capacity, is decreased in PTSD and correlated with symptom severity and markers of inflammation.

Bersani FS, Wolkowitz OM, Lindqvist D, Yehuda R, Flory J, Bierer LM, Makotine I, Abu-Amara D, Coy M, Reus VI, Epel ES, Marmar C, Mellon SH.

Brain Behav Immun. 2016 Feb;52:153-60. doi: 10.1016/j.bbi.2015.10.015. Epub 2015 Oct 26.

PMID:
26515034
11.

Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure.

Tang WH, Shrestha K, Troughton RW, Borowski AG, Klein AL.

Congest Heart Fail. 2011 May-Jun;17(3):105-9. doi: 10.1111/j.1751-7133.2011.00221.x. Epub 2011 Mar 31.

12.

B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction.

Price JF, Thomas AK, Grenier M, Eidem BW, O'Brian Smith E, Denfield SW, Towbin JA, Dreyer WJ.

Circulation. 2006 Sep 5;114(10):1063-9. Epub 2006 Aug 28.

13.

N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R.

N Engl J Med. 2005 Feb 17;352(7):666-75.

15.

Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography.

Sourij H, Meinitzer A, Pilz S, Grammer TB, Winkelmann BR, Boehm BO, März W.

Atherosclerosis. 2011 Sep;218(1):220-5. doi: 10.1016/j.atherosclerosis.2011.04.041. Epub 2011 May 10.

PMID:
21632053
16.

Transthoracic bioimpedance and brain natriuretic peptide assessment for prognostic stratification of outpatients with chronic systolic heart failure.

Malfatto G, Corticelli A, Villani A, Giglio A, Della Rosa F, Branzi G, Facchini M, Parati G.

Clin Cardiol. 2013 Feb;36(2):103-9. doi: 10.1002/clc.22086. Epub 2013 Feb 3.

17.

Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease.

Dini FL, Buralli S, Bajraktari G, Elezi S, Duranti E, Metelli MR, Carpi A, Taddei S.

Biomed Pharmacother. 2010 May;64(5):339-42. doi: 10.1016/j.biopha.2009.09.008. Epub 2009 Nov 5.

PMID:
19944559
18.
19.

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA.

Circ Heart Fail. 2013 Mar;6(2):219-26. doi: 10.1161/CIRCHEARTFAILURE.112.000129. Epub 2013 Feb 8.

20.

Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.

Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H.

Int J Cardiol. 2005 Aug 18;103(2):182-6.

PMID:
16080978

Supplemental Content

Support Center